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Abstract: This article contains a review of the clinical aspects of testosterone replacement in 
androgen deficiency of the aging male.
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As men age, there is a gradual decline in testosterone of 1.0% and 1.2% (total and 
free levels, respectively), annually, after age 40. Free testosterone levels decline faster 
because of the associated increase in sex hormone-binding globulin.1, 2
This phenomenon is known as andropause, or as (partial) androgen deficiency 
of the aging male [(P) ADAM], when it is associated with signs and symptoms of 
androgen deficiency.3
ADAM can be defined biochemically, or clinically. Biochemically, a total testoster-
one cut off of 325 ng% (11.3 nmol/L) leads to a diagnosis of androgen deficiency in 
20% of men .60 years, 30% of men .70 years, and 50% of men .80 years.4 Many 
of these men, however, have no clinical features of testosterone deficiency, and risk 
being overtreated.
The clinical approach utilizes symptoms and signs of androgen deficiency. These, 
however, are nonspecific, and may be due to other illnesses. Lethargy, asthenia, lack of 
concentration, disturbed sleep, irritability, and depression are the common symptoms 
which have multiple etiologies.
Both clinical and biochemical parameters, therefore, must be used to define ADAM, 
before it is treated.
Symptoms and signs
The signs and symptoms of androgen deficiency may be nonspecific. In general, the 
features can be classified as physical, psychological, and sexual symptoms and signs, 
and laboratory abnormalities. These are listed below:
Physical symptoms/signs
•	 decreased muscle bulk
•	 increased adiposity
•	 loss of secondary body hair
•	 loss of vigorClinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Psychological symptoms/signs
•	 low mood
•	 poor cognition
•	 irritability
Sexual symptoms/signs
•	 declining sexual desire
•	 erectile dysfunction
Laboratory abnormalities
•	 loss of bone mineral density
•	 atherosclerosis
Effects of treatment
Physiologic androgen replacement can be differentiated from 
pharmacological androgen therapy. Physiologic androgen 
replacement, which is the focus of this review, aims to achieve 
normal androgen levels in serum and tissue, so that the signs 
and symptoms of androgen deficiency are alleviated in a 
hypogonadal male. It does not target a specific organ   system, 
and does not try to reach supraphysiological levels. On the 
other hand, pharmacological androgen therapy, such as for 
anemia due to bone marrow failure, or for endometriosis, is 
aimed at producing specific effects on specific tissues.
A long term (3 years long) trial has demonstrated increase 
in lean mass, with reduction in fat mass in 96 men aged 
73 years who wore a scrotal testosterone patch delivering 
6 mg testosterone every 24 hours.5,6
No change was noted in muscle strength and function, 
bone density, or subjective perception of energy or sexual 
functions with testosterone.
Though the prostatic specific antigen concentration 
increased slightly over the first six months, it remained stable 
for the remainder of the study.5 Urodynamic parameters and 
number of clinically significant prostate events were similar 
in the testosterone and placebo groups. Hemoglobin and 
hematocrit increased significantly in the testosterone group 
over the first 6 months.
Libido and sexual function improved with transdermal tes-
tosterone replacement in clear cut cases of hypogonadism.7
Other randomized, placebo controlled trials in older 
healthy men have shown beneficial effects of sublingual 
testosterone in functional performance, hand grip strength, 
lean body mass (+3.8 kg), bone mineral density at lumbar 
spine (+10.2 ± 1.4%), and hip (+2.7 ± 0.7%) at 36 months, 
along with a decrease in low density lipoprotein (LDL) 
cholesterol.8
Simultaneous use of finasteride9 in one study was 
shown to reduce the increase in prostate volume seen with 
exogenous testosterone in hypogonadal men. Testosterone 
replacement, either injectable or noninjectable, in elderly 
men leads to only modest or no decrease in plasma HDL.10–12 
The levels of LDL are inversely proportional to testosterone 
concentration.13,14
Testosterone supplementation of middle aged men 
reduces visceral fat, serum glucose, blood pressure, and 
improves insulin sensitivity.15,16 One trial with oral testos-
terone has shown reduction in symptoms of angina in men 
with coronary heart disease.17 A recent study, however, has 
been stopped prematurely18 because of excess cardiovascular 
events noted in the testosterone gel-treated arm of a study 
involving elderly community-dwelling men (mean age 
73 years) with low testosterone levels.
Studies have shown improved spatial and verbal memory 
with supraphysiological testosterone levels,19 and improved 
spatial and working memory with high normal levels in 
healthy older men.20
Results related to major depression have been conflicting, 
with one study suggesting a benefit,21 but another reporting 
no effect of supraphysiological testosterone therapy in this 
condition.22
To treat or not to treat
Treatment should be decided based on both clinical and bio-
chemical parameters.23 Biochemical confirmation is carried 
out if patients present with signs and symptoms suggestive 
of androgen deficiency. Diagnosis should not be made during 
an acute or subacute illness.
An arbitrary cut off of 200 mg% (7.0 nmol/L) has been 
suggested.24,25 This cut off is lower than that suggested by 
earlier population-based studies.4 The discrepancy may be a 
reflection of the greater understanding of need for optimal 
androgen levels by endocrinologists.
The clinical features which demonstrate highest associa-
tion with low testosterone levels are decreased morning erec-
tions, decreased sexual desire, erectile dysfunction, and low 
physical activity.26 Physical and sexual symptoms are likely 
to provide more specificity than psychological symptoms.26
Laboratory evaluation is ideally carried out by measuring 
early morning total or free testosterone levels. One should 
be aware that total testosterone can be affected by changes 
in sex hormone binding globulin (SHBG) concentration. 
SHBG concentrations are reduced in obesity, nephrotic 
syndrome, hypothyroidism, and use of glucocorticoids, Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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progestins, and androgenic steroids.27 SHBG cause increases 
in aging,   cirrhosis, hyperthyroidism, HIV infection, and 
estrogen use.
The aim of treatment is to return testosterone value to 
‘physiologic’ age-matched levels. Titration of dose is carried 
out according to serum testosterone levels.
The duration of testosterone therapy is uncertain, and 
may depend on changes in prostate size, PSA levels, and 
hematocrit.
Choosing a testosterone 
preparation
Various testosterone preparations are available for use.3
Oral testosterone undecanoate, formulated in oleic acid, 
is absorbed through the lymphatics into systemic   circulation, 
bypassing the liver. Doses of 40 to 80 mg two to three 
times a day with meals are used, but clinically responses 
are variable.
Oral testosterone should be used initially for all patients 
requiring androgen replacement, because it has the advantage 
of being easy to discontinue in case of an adverse clinical 
reaction.
Injectable and transdermal preparations are also avail-
able. Esterification of testosterone at the 17-β hydroxyl 
position makes it hydrophobic and increase the duration of 
action, in a manner directly proportional to the length of the 
side chain.
Testosterone undecanoate28 has the longest duration of 
action, and is injected in a dose of 1,000 mg, followed by 
a similar dose at 6 weeks, and then every 12 weeks. Stable 
levels of testosterone are achieved, but the large volume 
(4 mL) may cause some discomfort. Dose titration can be 
done by varying the dose (1–4 mL) or frequency (6 to 8 to 
12 weekly) of injections.
A mixture of testosterone enanthate, cypionate, and 
  propionate is also available as a total dose of 100 mg and 
250 mg, to be administered IM every 14 to 21 days. It is easy 
to use, and is effective, but leads to peaks or supraphysi-
ological concentrations, and lows or hypogonadal ranges 
of testosterone, during the mid-phase and late phase of the 
dosing interval.
Transdermal preparations are available for nongenital 
use and scrotal use as well. The gel is applied in a dose of 
5 to 20 g on scrotal skin, and it achieves uniform concentra-
tions over 24 hours. It is easy to use, invisible, and allows 
for flexibility of dosing, but can be transferred through skin 
to skin contact.
Nongenital 5 mg patches also available. Controlled 
release, bioadhesive 30 mg testosterone tablets can be applied 
every 24 hours to the buccal mucosa. Implant of crystalline 
testosterone can be inserted into the subcutaneous tissue, 
and maintain adequate serum testosterone levels for up to 
6 months, if used in a dose of 4 to 6 200 mg implants.
Oral 17-α alkylated testosterone derivatives are no longer 
used, because of potential hepatotoxicity.
Choice of the testosterone preparation depends on various 
factors. In general, injectable preparations are more economi-
cal than others. Oral and transdermal preparations are easier 
to administer, while some patients prefer the occasional 
injectable therapy. Oral testosterone has a quicker onset and 
shorter duration of action, while transdermal testosterone 
leads to less increase in PSA than oral preparations.29
Contraindications
The contraindications to testosterone therapy are listed 
below:
1.  Metastatic prostate cancer
2.  Breast cancer
3.  Undiagnosed prostate nodule or induration
4.  Unexplained PSA elevation .3 ng/mL
5.  Erythrocytosis (hematocrit .50%)
6.  Severe BPH symptoms (AUA/IPSS .19)
7.  Unstable severe congestive heart failure (class III or IV)
Adverse events
Testosterone-related adverse events are usually uncommon. 
However, frequently seen side effects include acne, oily skin, 
breast tenderness, erythropoiesis, detection of subclinical 
prostate cancer, increase in prostate volume, and growth of 
metastatic prostate cancer. None of the randomized clinical 
trials on testosterone has been powered for long-term pros-
tate safety. Most studies, however, have shown no change 
in prostate size or urine flow prostate symptom score with 
testosterone.30
There is only weak evidence of an association of testoster-
one replacement with gynaecomastia, male pattern baldness, 
worsening of BPH symptoms, growth of breast cancer, and 
induction or worsening of obstructive sleep apnea.3
Monitoring of testosterone therapy
Men should be followed up for 3 months after starting 
  therapy, and annually thereafter. The aim should be to main-
tain serum testosterone levels in the mid normal range. Serum 
LH and FSH are not used to monitor therapy.9Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Hemoglobin, hematocrit, digital prostate examinations, 
and PSA should be checked regularly.
Patients on injectable testosterone mixtures should have 
their testosterone levels assessed midway between injections, 
aiming for a level 350–700 ng/mL. Those on the injectable 
testosterone undecanoate should have a serum testosterone 
assessment prior to the injection. Levels should be assessed 
3 to 12 hours after applying transdermal patch, 3 to 5 hours 
after ingesting oral testosterone undecanoate, at any time 
while on a testosterone gel, and just prior to inserting a 
buccal tablet.
Hematocrit should be checked at baseline, at 3 months, then 
annually. Testosterone should be stopped if hematocrit rises 
to .54% and reinitiated slowly when it falls to below 50%.
Digital rectal examination and PSA should be carried out 
at baseline, at 3 months, and then as clinically indicated.9
A urology consultation should be sought if serum PSA 
rises above 4.0 ng/mL, increases by 1.4 ng/mL or more over 
12 months, or .0.4 ng/mL/year for 2 years. A urology con-
sultation is also indicated if a prostate abnormality is noted 
or the AUA/IPSS symptoms score rises above 19.
Conclusion
Testosterone replacement is an effective method of   treating 
hypogonadism in elder men, if used judiciously. An 
  understanding of possible benefits and risks, judicious choice 
of the testosterone preparation, combined with regular moni-
toring, makes testosterone replacement a beneficial choice 
for older men with both biochemical and clinical evidence 
of androgen deficiency. Both physicians and patients must 
be aware of the possible side effects and complications of 
testosterone therapy.
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